What the company does
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of …
What the weekly tape is saying
ALCLS closed the latest completed week at 2.76 EUR. The 4-week return is -22.9% and the 12-week return is -5.7%. Trend Signal is inactive, Market Dynamics is -0.35. Setup signature: Risk-first tape with a 18/100 composite read.
A compressed read of the whole setup
The radar blends trend persistence, momentum, Market Dynamics, Relative Strength, volume confirmation, and risk control into one weekly cockpit.
Scoreboard
16-week signal tape
Price, Trend Line, and Fair Value
Weekly price context with the latest close, trend position, Fair Value gap, drawdown, and 52-week range location.
52-week price path
Price map
- Trend Line
- 3.45 EUR
- Vs Trend Line
- -19.9%
- Fair Value
- 2.30 EUR
- Vs Fair Value
- 20.2%
- 52W High
- 4.84 EUR
- 52W Low
- 1.23 EUR
- Drawdown
- -42.9%
- Range Position
- 42.4%
Returns and trend persistence
Return windows separate the latest week from short-term and medium-term follow-through.
Return windows
Trend read
- Active Streak
- 0 weeks
- 52W Active Weeks
- 31
- 52W Active Breadth
- 59.6%
- Sector Scope
- FR Healthcare
- Sector Rank
- 7 of 76
- Sector Percentile
- 92.0%
Sector and industry pulse
Peer breadth helps separate a stock-specific move from a broader group rotation.
FR Healthcare
- Tracked Peers
- 76
- 4W Rank
- 66 of 76
- Avg 1W
- -2.1%
- Avg 4W
- -5.9%
- Trend Breadth
- 28.9%
- Positive MD
- 48.7%
FR Biotechnology
- Tracked Peers
- 33
- 4W Rank
- 24 of 33
- Avg 1W
- -2.8%
- Avg 4W
- -11.9%
- Trend Breadth
- 27.3%
- Positive RS
- 21.2%
Pressure, Relative Strength, and expectation
Market Dynamics and Relative Strength show whether buying pressure and relative leadership are confirming the price move.
Dynamics path
Signal state
- Market Dynamics
- -0.35
- 4W MD Change
- -324.1%
- Relative Strength
- -12.33
- 4W RS Change
- -151.5%
- Expectation
- Negative
- Probability
- 41.11%
Participation and confirmation
Volume tells us whether the latest weekly move is being confirmed by unusual participation.
52-week volume profile
Volume map
- Latest Volume
- 2.0M
- 13W Average
- 1.5M
- 52W Average
- 2.0M
- Vs 13W
- 1.3x
- Vs 52W
- 1.0x
Volatility, downside weeks, and return shape
A compact risk profile shows whether the move is steady, volatile, or being driven by sharp one-week jumps.
26-week return distribution
Risk map
- 13W Volatility
- 9.9%
- 52W Volatility
- 11.0%
- Upside Weeks
- 26
- Downside Weeks
- 26
- Downside Breadth
- 50.0%
- Avg Gain / Loss
- 10.4% / -6.3%
Classification, opportunities, risks, and watch points
Top-level read across company classification, constructive evidence, caution points, and the next things that matter.
Classification
- Exchange
- PAR
- Country
- FR
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- EUR
- Market Cap
- 301.4M
Opportunity signals
- Price is above Fair Value, showing premium demand versus the model.
- Latest weekly return ranks in the strongest part of its sector group.
Risk signals
- Trend Signal is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Market Dynamics is negative, which weakens the current setup.
- The share remains more than 20% below its 52-week high.
Watch next
- Trend Line remains the key weekly regime level.
- Market Dynamics is the pressure gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Recent completed weeks
The latest weekly rows behind the report snapshot.
| Week | Close | Return | Trend | Fair Value | MD | RS | Volume | Signal |
|---|---|---|---|---|---|---|---|---|
| 12 Jun 2026 | 2.76 EUR | 4.7% | 3.45 EUR | 2.30 EUR | -0.35 | -12.33 | 2.0M | Off |
| 5 Jun 2026 | 2.64 EUR | -14.2% | 3.47 EUR | 2.29 EUR | -0.13 | -14.19 | 1.9M | Off |
| 29 May 2026 | 3.08 EUR | 0.4% | 3.48 EUR | 2.29 EUR | -0.04 | 1.22 | 1.2M | Off |
| 22 May 2026 | 3.06 EUR | -14.5% | 3.48 EUR | 2.28 EUR | -0.06 | 2.75 | 1.4M | Off |
| 15 May 2026 | 3.58 EUR | 12.1% | 3.48 EUR | 2.27 EUR | -0.08 | 23.92 | 1.5M | Off |
| 8 May 2026 | 3.20 EUR | -3.8% | 3.47 EUR | 2.26 EUR | -0.04 | 10.01 | 877.2K | Off |
| 1 May 2026 | 3.33 EUR | 0.6% | 3.49 EUR | 2.25 EUR | -0.27 | 15.72 | 753.5K | Off |
| 24 Apr 2026 | 3.31 EUR | -12.6% | 3.48 EUR | 2.24 EUR | -0.50 | 15.82 | 1.4M | Off |
| 17 Apr 2026 | 3.78 EUR | 18.6% | 3.47 EUR | 2.23 EUR | -0.77 | 29.87 | 5.5M | Off |
| 10 Apr 2026 | 3.19 EUR | 2.7% | 3.44 EUR | 2.22 EUR | -1.26 | 13.33 | 844.4K | Off |
| 3 Apr 2026 | 3.10 EUR | 10.5% | 3.43 EUR | 2.21 EUR | -1.29 | 15.83 | 714.1K | Off |
| 27 Mar 2026 | 2.81 EUR | -4.1% | 3.40 EUR | 2.20 EUR | -1.35 | 9.87 | 821.9K | Off |
| 20 Mar 2026 | 2.93 EUR | -7.0% | 3.38 EUR | 2.20 EUR | -1.29 | 16.53 | 929.4K | Off |
| 13 Mar 2026 | 3.15 EUR | -0.3% | 3.37 EUR | 2.19 EUR | -1.25 | 23.01 | 1.2M | Off |